FDA
-
-
-
-
-
-
-
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
-
-
-
-
-
-
-
KALA BIO closes $10 million stock offering at $1 per share
-
-
-
-
-
-
-
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
-
-
-
-
-
-
-
KALA BIO completes enrollment in CHASE trial for eye disease treatment
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Kala Pharmaceuticals (KALA), PT $15
-
-
-
-
-
-
-
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
-
-
-
-
-
-
-
KALA BIO Announces $12,500,000 Private Placement
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

